Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Klaria Pharma Holding AB: Klaria Interim Report Q3 2025

Klaria Pharma Holding
Download udgivelse

Klaria Interim Report

1 July - 30 September 2025

Summary of the interim report

Third quarter of 2025

The group in total

- Net sales 0.0 MSEK (0.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 4.8 MSEK (4.7 MSEK)

- Profit after tax amounted to -8.7 MSEK (-7.9 MSEK)

- Earnings per share for the quarter amounted to -0.04 SEK (-0.06 SEK)

- Cash flow from operating activities amounted to -31.2 MSEK (-3.5 MSEK)

- Liquid assets on the balance sheet date amounted to 2.5 MSEK (0.5 MSEK)

- Group equity as of September 30 amounted to 4.5 MSEK (12.9 MSEK)

- Equity in the parent company as of September 30 amounted to 94.5 MSEK 139.7 MSEK)

- The company received 31.8 MSEK after issue costs from the issue of 101,217,381 shares in July

The period January-September 2025

The group in total

- Net sales 9.0 MSEK (0.1 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 15.3 MSEK (12.8 MSEK)

- Profit after tax amounted to -30.4 MSEK (-32.2 MSEK)

- Earnings per share for the quarter amounted to -0.18 SEK (-0.26 SEK)

- Cash flow from operating activities amounted to -32.6 MSEK (-13.2 MSEK)

- The company received 9.7 MSEK from the issue of convertibles in June

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.